Here you can find the latest TOPADUR news & events.
CHF 1.76 million is awarded from Innosuisse for the Phase 2a clinical trial with TOP-N53 in the treatment of digital ulcers
Topadur Pharma AG and Juvic Inc. Launch Transnational Collaboration for the Disease Management of Systemic Sclerosis
TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with Yonsei University and Juvic Inc.
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.
TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.
Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.
Do you need more information or references? Media contact